Essa Pharma Inc - Understand $epix stock

$EPIX Market Cap: $79.42 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$27.67M

TTM

Current Assets

$132.1M

Q2 2024

Current Liabilities

$3.575M

Q2 2024

Current Ratio

3694.8%

Q2 2024

Total Assets

$132.7M

Q2 2024

Total Liabilities

$3.805M

Q2 2024

Book Value

$128.9M

Q2 2024

Cash

$85.99M

Q2 2024

P/E

-2.870

Nov 11, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$62.77K	$82.49K	$66.76K	$70.00K	$70.00K	$70.00K	$50.00K		$30.00K	$40.00K
Gross Profit	-$62.77K	-$82.49K	-$66.76K	-$70.00K	-$70.00K	-$70.00K	-$50.00K		-$30.00K	-$40.00K
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$11.37M	$12.56M	$12.89M	$11.37M	$5.460M	$5.930M	$5.090M	$5.580M	$5.460M	$1.190M	$500.0K	$350.0K	$270.0K
YoY Change	-9.44%	-2.61%	13.41%	108.24%	-7.93%	16.5%	-8.78%	2.2%	358.82%	138.0%	42.86%	29.63%
% of Gross Profit
Research & Development	$21.32M	$24.42M	$24.26M	$12.15M	$6.696M	$5.000M	$10.87M	$13.06M	$10.30M	$1.690M	$500.0K	$1.550M	$680.0K
YoY Change	-12.67%	0.64%	99.73%	81.39%	33.92%	-54.0%	-16.77%	26.8%	509.47%	238.0%	-67.74%	127.94%
% of Gross Profit
Depreciation & Amortization						$30.00K	$50.00K	$70.00K	$40.00K	$20.00K	$20.00K	$30.00K	$30.00K
YoY Change						-40.0%	-28.57%	75.0%	100.0%	0.0%	-33.33%	0.0%
% of Gross Profit
Operating Expenses	$32.14M	$36.97M	$37.17M	$24.14M	$12.75M	$10.96M	$16.01M	$18.70M	$15.81M	$2.900M	$1.020M	$1.920M	$980.0K
YoY Change	-13.07%	-0.52%	53.97%	89.26%	16.37%	-31.54%	-14.39%	18.28%	445.17%	184.31%	-46.88%	95.92%
Operating Profit	-$32.20M	-$37.06M	-$37.23M	-$24.21M	-$12.82M	-$11.03M	-$16.06M		-$15.84M	-$2.940M
YoY Change	-13.09%	-0.47%	53.8%	88.77%	16.27%	-31.32%			438.78%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$5.560M	$1.759M	$313.3K	-$220.0K	-$560.0K	-$710.0K	$6.490M	$5.710M	$810.0K	-$30.00K	-$10.00K	-$10.00K	$10.00K
YoY Change	216.16%	461.29%	-242.42%	-60.71%	-21.13%	-110.94%	13.66%	604.94%	-2800.0%	200.0%	0.0%	-200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$26.58M	-$35.22M	-$36.84M	-$23.73M	-$12.72M	-$11.60M	-$4.380M	-$12.99M	-$9.360M	-$1.810M	-$1.030M	-$1.930M	-$980.0K
YoY Change	-24.52%	-4.41%	55.22%	86.6%	9.65%	164.84%	-66.28%	38.78%	417.13%	75.73%	-46.63%	96.94%
Income Tax	$1.600K	-$111.8K	-$34.35K	-$288.6K	$37.92K	$30.00K	$120.0K	$150.0K
% Of Pretax Income
Net Earnings	-$26.58M	-$35.10M	-$36.81M	-$23.45M	-$12.76M	-$11.63M	-$4.500M	-$13.14M	-$9.360M	-$1.810M	-$1.030M	-$1.930M	-$980.0K
YoY Change	-24.27%	-4.62%	56.98%	83.79%	9.69%	158.44%	-65.75%	40.38%	417.13%	75.73%	-46.63%	96.94%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.60	-$0.80	-$0.96
Diluted Earnings Per Share	-$0.60	-$0.80	-$956.5K	-$1.045M	-$1.514M	-$2.545M	-$3.103M	-$9.733M	-$10.17M	-$2.321M	-$1.321M	-$2.644M	-$1.531M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$148.1M	$167.2M	$194.9M	$78.33M	$53.32M	$14.83M	$3.960M	$8.990M	$1.580M	$3.700M	$230.0K	$830.0K	$240.0K
YoY Change	-11.46%	-14.21%	148.85%	46.91%	259.54%	274.49%	-55.95%	468.99%	-57.3%	1508.7%	-72.29%	245.83%
Cash & Equivalents	$33.70M	$57.08M	$137.8M
Short-Term Investments	$114.4M	$110.2M	$57.10M	$22.01M	$0.00
Other Short-Term Assets	$585.4K	$1.816M	$2.182M	$1.660M	$620.0K	$470.0K	$1.070M	$1.020M	$1.660M	$60.00K	$0.00	$10.00K	$0.00
YoY Change	-67.76%	-16.79%	31.44%	167.74%	31.91%	-56.07%	4.9%	-38.55%	2666.67%		-100.0%
Inventory
Prepaid Expenses
Receivables	$135.1K	$6.210K	$489.0K	$310.0K	$360.0K	$300.0K	$30.00K	$20.00K	$3.850M	$60.00K	$10.00K	$160.0K	$70.00K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$148.8M	$169.1M	$197.6M	$80.30M	$54.30M	$15.60M	$5.060M	$10.02M	$7.090M	$3.830M	$240.0K	$990.0K	$320.0K
YoY Change	-11.99%	-14.44%	146.07%	47.88%	248.08%	208.3%	-49.5%	41.33%	85.12%	1495.83%	-75.76%	209.38%
Property, Plant & Equipment	$68.01K	$186.5K	$308.3K			$0.00	$100.0K	$130.0K	$170.0K	$10.00K	$0.00
YoY Change	-63.53%	-39.51%				-100.0%	-23.08%	-23.53%	1600.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$257.2K	$259.5K	$259.5K	$280.0K	$270.0K	$200.0K	$210.0K		$0.00
YoY Change	-0.85%	0.0%	-7.34%	3.7%	35.0%	-4.76%
Total Long-Term Assets	$325.3K	$446.0K	$567.7K	$270.0K	$270.0K	$420.0K	$550.0K	$380.0K	$450.0K	$380.0K	$420.0K	$460.0K	$460.0K
YoY Change	-27.07%	-21.45%	110.27%	0.0%	-35.71%	-23.64%	44.74%	-15.56%	18.42%	-9.52%	-8.7%	0.0%
Total Assets	$149.1M	$169.5M	$198.2M	$80.57M	$54.57M	$16.02M	$5.610M	$10.40M	$7.540M	$4.210M	$660.0K	$1.450M	$780.0K
YoY Change
Accounts Payable	$2.028M	$954.6K	$1.426M	$680.0K	$1.360M	$520.0K	$1.640M	$3.540M	$2.090M	$590.0K	$180.0K	$130.0K	$40.00K
YoY Change	112.47%	-33.05%	109.69%	-50.0%	161.54%	-68.29%	-53.67%	69.38%	254.24%	227.78%	38.46%	225.0%
Accrued Expenses	$1.467M	$1.356M	$2.504M	$520.0K	$210.0K
YoY Change	8.19%	-45.85%	381.5%	147.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00	$0.00	$3.710M	$2.820M	$2.030M
YoY Change				-100.0%	31.56%	38.92%
Total Short-Term Liabilities	$3.495M	$2.310M	$3.930M	$1.200M	$5.570M	$3.340M	$3.780M	$3.630M	$2.090M	$590.0K	$180.0K	$130.0K	$40.00K
YoY Change	51.28%	-41.21%	227.47%	-78.46%	66.77%	-11.64%	4.13%	73.68%	254.24%	227.78%	38.46%	225.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$3.500M	$5.930M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change					-100.0%	-40.98%
Other Long-Term Liabilities	$0.00	$76.42K	$230.6K	$130.0K	$20.00K	$20.00K	$170.0K	$7.310M	$990.0K	$1.640M	$0.00
YoY Change	-100.0%	-66.86%	77.38%	550.0%	0.0%	-88.24%	-97.67%	638.38%	-39.63%
Total Long-Term Liabilities	$0.00	$76.42K	$230.6K	$130.0K	$20.00K	$3.520M	$6.100M	$7.310M	$990.0K	$1.640M	$0.00	$0.00	$0.00
YoY Change	-100.0%	-66.86%	77.38%	550.0%	-99.43%	-42.3%	-16.55%	638.38%	-39.63%
Total Liabilities	$3.495M	$2.387M	$4.160M	$1.330M	$5.590M	$6.870M	$9.880M	$10.94M	$3.080M	$2.230M	$180.0K	$130.0K	$40.00K
YoY Change	46.43%	-42.63%	212.8%	-76.21%	-18.63%	-30.47%	-9.69%	255.19%	38.12%	1138.89%	38.46%	225.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	44.09M	44.04M	38.48M
Diluted Shares Outstanding	44.09M	44.04M	38.48M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $79.42 Million

About ESSA Pharma Inc

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The firm is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The firm is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Industry: Pharmaceutical Preparations Peers: Portage Biotech Inc Fusion Pharmaceuticals Inc. Xenon Pharmaceuticals Inc.